WebOct 7, 2024 · Continuous single-agent ibrutinib affords survival benefit in the first-line treatment of chronic lymphocytic leukemia (CLL), but there is increasing desire for convenient, all-oral, time-limited treatment options that may be safely administered in the outpatient setting. ... These results show the potential for fixed-duration treatment with ... WebApr 10, 2024 · Treatment with venetoclax + rituximab normalized the number of T cells and natural killer cells. Infection rates were low and higher during treatment than after …
How I manage CLL with venetoclax-based treatments Blood ...
Web1 hour ago · Owen notes that she is excited to see how findings from the phase 3 GLOW trial (NCT03462719) of elderly or unfit patients with CLL who were treated with fixed … WebMar 28, 2024 · Allan JN, Flinn IW, Siddiqi T, et al. Fixed-duration ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia in patients with high-risk features: … small wrecker truck bodies
European Commission Approves IMBRUVICA® (ibrutinib) in a …
WebDec 9, 2024 · The current standard of care with targeted agents is largely divided into 2 approaches: continuous therapy with a Bruton’s tyrosine kinase (BTK) inhibitor (BTKi) ± anti-CD20 monoclonal antibody (mAb), or 1-year duration venetoclax plus obinutuzumab (VO). WebJul 7, 2024 · The primary analysis of the fixed-duration (FD) cohort of the phase II CAPTIVATE trial ( NCT02910583) evaluating ibrutinib (I) in combination with venetoclax (V) as first-line therapy in patients with CLL/small lymphocytic lymphoma (SLL) has been previously summarized by the Lymphoma Hub. The primary analysis of the FD cohort … WebNov 10, 2024 · Leukemia and Fixed Duration Treatment Venetoclax plus obinutuzumab - the first chemotherapy-free, fixed-duration first line CLL treatment approved by Health … hilary hotchkiss